FGFR inhibitors in urothelial cancer: Contextualizing THOR within the new treatment landscape

Kriti Mittal, Monika Joshi

Research output: Contribution to journalComment/debatepeer-review

Abstract

As frontline treatment of advanced urothelial cancer (UC) evolves, optimal sequencing of subsequent therapies remains unclear. The phase 3 THOR trial compared the efficacy of erdafitinib to chemotherapy or immunotherapy in FGFR3/2-altered advanced UC. THOR offers valuable data informing sequencing strategies, reinforcing the need for molecular testing in UC.

Original languageEnglish (US)
Pages (from-to)176-178
Number of pages3
JournalMed
Volume5
Issue number3
DOIs
StatePublished - Mar 8 2024

All Science Journal Classification (ASJC) codes

  • General Medicine

Cite this